Kura Oncology to Participate in Upcoming Investor Conferences

On March 1, 2023 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences (Press release, Kura Oncology, MAR 1, 2023, View Source [SID1234627947]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A "Leukemia Corporate Panel" discussion at the Cowen Health Care Conference in Boston at 12:50 p.m. ET / 9:50 a.m. PT on March 8, 2023;

A fireside chat at the Cowen Health Care Conference at 2:50 p.m. ET / 11:50 a.m. PT on March 8, 2023; and

A fireside chat at the Barclays Global Healthcare Conference in Miami at 2:35 p.m. ET / 11:35 a.m. PT on March 14, 2023.
Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following the events.